Melanoma & Skin Cancer

The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.

Neoadjuvant nivolumab/ipilimumab followed by TLND and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death in melanoma.

Induction encorafenib/binimetinib before nivolumab/ipilimumab did not improve PFS in unresectable or metastatic BRAF V600E/K–positive melanoma.

The COMBI-AD dataset is the longest follow-up to date of adjuvant treatment for patients with stage III melanoma.

An artificial intelligence-based smartphone app used by primary care physicians showed high diagnostic accuracy in detecting cutaneous melanoma.

Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma.

Mitchell Fane, PhD, has received a grant to investigate the role of aging in immune-regulated reactivation from metastatic melanoma.

The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued.

A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.

Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.

OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.

Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.

Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.

Vishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

John M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.

Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.

Omid Hamid, MD on adoptive T cell therapy, lifileucel, for patients with patients with advanced melanoma.

Experts discuss when to use the PD-1 inhibitor cemiplimab vs the hedgehog inhibitor vismodegib as neoadjuvant treatment in non-melanoma skin cancers.

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.